TNF

U.S. FDA Approves RINVOQ® (upadacitinib) as a Once-Daily Pill for Moderately to Severely Active Crohn's Disease in Adults

Retrieved on: 
星期四, 五月 18, 2023
Lymphoma, Extrapyramidal system, NORTH, CD, Smoker, Tears, Mayo Clinic, Vein, TNF, Gastroenterology, Allergy, Disease, TB, Infection, ABBV, Stroke, Clinical trial, Skin, Lung cancer, Research, Medicine, Artery, Inflammation, Fungus, Ulcerative colitis, Stomach, Crohn's disease, Dermatology, Cancer, Patient, AbbVie, Tuberculosis, Access, Risk, Rheumatology, Bacteria, FDA, CDAI, Death, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Virus, NYSE, Food, Medical device, Pharmaceutical industry, Dietary supplement

NORTH CHICAGO, Ill., May 18, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved RINVOQ® (upadacitinib) for the treatment of adults with moderately to severely active Crohn's disease who have had an inadequate response or intolerance to one or more TNF blockers.1 This is the seventh FDA approval for RINVOQ across rheumatology, dermatology, and gastroenterology, where it is now indicated in both ulcerative colitis and Crohn's disease.1

Key Points: 
  • "We're pleased that RINVOQ may provide this relief and is now available to treat Crohn's disease."
  • Overall, the safety profile observed in patients with Crohn's disease treated with RINVOQ was consistent with the known safety profile for RINVOQ in other indications.
  • Increased risk of death in people age 50+ with at least 1 heart disease risk factor.
  • For those with limited or no health insurance, AbbVie offers myAbbVie Assist, a patient assistance program that provides RINVOQ at no charge to those who qualify.

Ulcerative Colitis Treatment Market to Grow Exponentially by 2029- Brandessence Market Research

Retrieved on: 
星期四, 五月 18, 2023
MSD, Janus, Insurance, Prevalence, Interleukin 23, Abbott Laboratories, Enzyme, Diarrhea, Colon, Protein, Acquisition, Patient, Integrin, Eli Lilly and Company, Etrolizumab, Cell adhesion, Filgotinib, GSK plc, Pancolitis, Upadacitinib, USD, FMT, HIV disease progression rates, Allergan, Safety, GSK, Risankizumab, Mirikizumab, Takeda Pharmaceutical Company, Roche, MEA, Biomarker, Abdominal pain, Ulcerative colitis, UC, AbbVie, Cancer, Antibody, Bacillota, Johnson & Johnson, Sphingosine, Colitis, Module (mathematics), IL-12, TNF, JAK, Cramp, Pfizer, Inflammation, AstraZeneca, Eli Lilly, Ozanimod, Novartis, Cytokine, Health, Pharmaceutical industry, Dietary supplement, Vaccine, Health insurance, Bayer

The Global Ulcerative Colitis Treatment Market report curated by Brandessence Market Research provides a detailed overview of the market, including its size, growth rate, and key drivers.

Key Points: 
  • The Global Ulcerative Colitis Treatment Market report curated by Brandessence Market Research provides a detailed overview of the market, including its size, growth rate, and key drivers.
  • It examines various treatment options available for ulcerative colitis, including medications, surgery, and other therapies.
  • High Cost of Treatment: One of the major challenges in the ulcerative colitis treatment market is the high cost associated with the available treatment options.
  • FMT is being explored as a potential treatment option for ulcerative colitis, with ongoing clinical trials assessing its safety and efficacy.

Ulcerative Colitis Treatment Market to Grow Exponentially by 2029- Brandessence Market Research

Retrieved on: 
星期四, 五月 18, 2023
MSD, Janus, Insurance, Prevalence, Interleukin 23, Abbott Laboratories, Enzyme, Diarrhea, Colon, Protein, Acquisition, Patient, Integrin, Eli Lilly and Company, Etrolizumab, Cell adhesion, Filgotinib, GSK plc, Pancolitis, Upadacitinib, USD, FMT, HIV disease progression rates, Allergan, Safety, GSK, Risankizumab, Mirikizumab, Takeda Pharmaceutical Company, Roche, MEA, Biomarker, Abdominal pain, Ulcerative colitis, UC, AbbVie, Cancer, Antibody, Bacillota, Johnson & Johnson, Sphingosine, Colitis, Module (mathematics), IL-12, TNF, JAK, Cramp, Pfizer, Inflammation, AstraZeneca, Eli Lilly, Ozanimod, Novartis, Cytokine, Health, Pharmaceutical industry, Dietary supplement, Vaccine, Health insurance, Bayer

The Global Ulcerative Colitis Treatment Market report curated by Brandessence Market Research provides a detailed overview of the market, including its size, growth rate, and key drivers.

Key Points: 
  • The Global Ulcerative Colitis Treatment Market report curated by Brandessence Market Research provides a detailed overview of the market, including its size, growth rate, and key drivers.
  • It examines various treatment options available for ulcerative colitis, including medications, surgery, and other therapies.
  • High Cost of Treatment: One of the major challenges in the ulcerative colitis treatment market is the high cost associated with the available treatment options.
  • FMT is being explored as a potential treatment option for ulcerative colitis, with ongoing clinical trials assessing its safety and efficacy.

Approximately One-Year Post-Launch, AbbVie's Rinvoq Boasts Increasingly Favorable Perceptions Among Gastroenterologists for the Treatment of Ulcerative Colitis, According to Spherix Global Insights

Retrieved on: 
星期三, 五月 17, 2023
CD, Crohn's disease, TNF, Symantec Endpoint Protection, Takeda, IBD, JAK, SC, Mirikizumab, Eli Lilly and Company, JAK1, Adalimumab, Gastroenterology, Research, Ulcerative colitis, Eli Lilly, Inflammatory bowel disease, Infliximab, UC, AbbVie, Physician, CRL, BMS, FDA, Safety, RealTime, Vedolizumab, Pharmaceutical industry, Upadacitinib, Risankizumab, Pfizer

EXTON, Pa., May 17, 2023 /PRNewswire/ -- In March of 2022, the FDA approved AbbVie's JAK1 inhibitor, Rinvoq (upadacitinib), for the treatment of moderate to severe ulcerative colitis (UC).

Key Points: 
  • EXTON, Pa., May 17, 2023 /PRNewswire/ -- In March of 2022, the FDA approved AbbVie's JAK1 inhibitor, Rinvoq (upadacitinib), for the treatment of moderate to severe ulcerative colitis (UC).
  • According to Spherix's most recent RealTime Dynamix: Ulcerative Colitis (US) Q2 update, the majority of gastroenterologists are highly satisfied with the brand.
  • In fact, when pinned head-to-head against other leading UC brands on key agent attributes, Rinvoq has also made strong perceptual gains.
  • Spherix will continue to track the overall UC and CD markets and pulse gastroenterologists on their perceptions and intentions to use advanced therapies in their RealTime Dynamix services.

NImmune Biopharma Provides Update on Omilancor Clinical Development Programs in Ulcerative Colitis and Crohn’s Disease

Retrieved on: 
星期三, 五月 17, 2023
Biotechnology, FDA, Other Health, Health, General Health, Pharmaceutical, Biometrics, Other Science, Research, Science, Clinical Trials, Mayo, Myelocyte, Maintenance, FCP, Drug development, TNF, AE, IBD, NDA, A.I, Lupus, Ulcerative colitis, Psoriasis, Open-label trial, LANCL2, US, Acquisition, UC, Patient, Kelly Gebo, New Drug Application, Pharmaceutical industry, Phosphorus

Omilancor is a wholly-owned, once-daily gut-restricted oral first-in-class LANCL2 therapeutic entering Phase 3 clinical testing in UC patients.

Key Points: 
  • Omilancor is a wholly-owned, once-daily gut-restricted oral first-in-class LANCL2 therapeutic entering Phase 3 clinical testing in UC patients.
  • Dr. Josep Bassaganya-Riera, Founder & CEO of NImmune, said, "Following our successful acquisition of the LANCL therapeutic portfolio, we have made meaningful progress in advancing our clinical development programs for omilancor in IBD and NIM-1324 in lupus.
  • Importantly, the omilancor program has taken just over four years since inception to reach Phase 3 initiation, representing significant cost savings compared to traditional drug development timelines.
  • PACIFY II aims to randomize 652 active disease UC patients, with 326 patients receiving 440mg of omilancor and 326 patients receiving placebo.

EQS-News: Andera Partners co-leads a €40 million Series A of Dualyx, a Belgian biotech developing novel Treg therapies for autoimmune diseases

Retrieved on: 
星期一, 五月 15, 2023
TNFR2, Andera-ye Olya, TNF, VIB, Partner, GFF, Research, Regulatory T cell, Patient, BGV, Ghent University, PMV, Therapy, University of Würzburg, IND, KU Leuven, Independent, Pharmaceutical industry, Vaccine

Andera Partners co-leads a €40 million Series A of Dualyx, a Belgian biotech developing novel Treg therapies for autoimmune diseases

Key Points: 
  • Andera Partners co-leads a €40 million Series A of Dualyx, a Belgian biotech developing novel Treg therapies for autoimmune diseases
    The issuer is solely responsible for the content of this announcement.
  • Andera Partners co-leads a €40 million Series A of Dualyx, a Belgian biotech developing novel Treg therapies for autoimmune diseases
    Proceeds will enable the development of the Company’s lead autoimmune program DT-001, targeting TNFR2, as well as its pipeline of Treg-targeting candidates
    PARIS, FRANCE – MAY 15, 2023 – Andera Partners co-leads a €40 million Series A financing of Dualyx NV, a Ghent, Belgium based biotech developing next generation immune modulators.
  • Alongside Andera, Fountain Healthcare Partners and Forbion co-led the round, with support from existing investors V-Bio Ventures, BGV, PMV, VIB, HTGF, and GFF.
  • The funds raised will enable Dualyx to progress its lead autoimmune program DT-001, as well as its pipeline of Treg-targeting candidates.

Dualyx raises €40 million to progress Treg therapies for autoimmune diseases into the clinic

Retrieved on: 
星期一, 五月 15, 2023
TNFR2, TNF, VIB, KU, GFF, Research, Regulatory T cell, BGV, Ghent University, PMV, Therapy, University of Würzburg, Rest, IND, Independent, Vaccine

The funds raised will enable Dualyx to progress its lead autoimmune program DT-001, as well as its pipeline of Treg candidates.

Key Points: 
  • The funds raised will enable Dualyx to progress its lead autoimmune program DT-001, as well as its pipeline of Treg candidates.
  • Through state-of-the-art antibody development, Dualyx has developed an agonist to the receptor which shows highly selective activation of regulatory T cells (Tregs).
  • DT-001 holds promise to be a game-changing treatment option for a broad range of autoimmune diseases.
  • I’m therefore delighted to join the Board as Chairman while Dualyx heads towards the clinic,” commented Bernard Coulie, Independent Chairman of Dualyx.

University of Oxford’s Kennedy Institute of Rheumatology Partners with Absci to Accelerate AI-Driven Immunotherapies

Retrieved on: 
星期四, 五月 11, 2023
Partnership, Probability, Drug development, University, TNF, IBD, Adalimumab, Genomics, Antibody, Autoimmunity, Ulcerative colitis, Inflammatory bowel disease, Kennedy Institute, Crohn's disease, Patient, Clinical research, Immune-mediated inflammatory diseases, Kennedy, Kennedy Institute of Ethics Journal, Synthetic biology, Pharmaceutical industry, Vaccine, Rheumatology

It takes an average of ten years and costs more than $1 billion to bring a new drug to market.

Key Points: 
  • It takes an average of ten years and costs more than $1 billion to bring a new drug to market.
  • Absci will use generative AI models with The Kennedy Institute’s genomics datasets to identify novel antibodies from patients with exceptional immune responses to inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis.
  • Then, using its reverse immunology approach, Absci will computationally re-assemble antigen-antibody pairs as promising potential starting points for drug development.
  • Absci and The Kennedy Institute will work together to accelerate the discovery and development of other promising drug targets and therapies.

Study Shows Preventive Effects and Protective Potential of Astaxanthin on Collagen Damage

Retrieved on: 
星期二, 五月 9, 2023
Elasticity, Radical, Human, Food, Diet, TNF, Neutrophil, Cartilage, Inflammation, Element, Doctor of Philosophy, Haematococcus, Sunlight, Journal, Joint, Collagen, Cauchy stress tensor, Science and technology in Asia, III, Skin, Dietary supplement, Tanning (leather)

BRANCHBURG, N.J., May 9, 2023 /PRNewswire/ -- A study recently published in the Journal of Food & Nutritional Sciences, found that Lycored's astaxanthin prevented against collagen damage from neutrophils, discovering its potential to protect collagen and enhance skin health.

Key Points: 
  • BRANCHBURG, N.J., May 9, 2023 /PRNewswire/ -- A study recently published in the Journal of Food & Nutritional Sciences, found that Lycored's astaxanthin prevented against collagen damage from neutrophils, discovering its potential to protect collagen and enhance skin health.
  • This study assessed the addition of astaxanthin to neutrophils, the key players in the skin's immune response and photoaging, and the combined effects on collagen presence.
  • The addition of 50 uM of astaxanthin prevented collagen I loss by 28.1±8%, and collagen III loss by 49.4±5.9%.
  • Lycored's astaxanthin uses algae-derived (Haematococcus pluvialis) astaxanthin carotenoid with anti-oxidative and anti-inflammatory properties that provides a multitude of science-backed benefits.

Study Shows Preventive Effects and Protective Potential of Astaxanthin on Collagen Damage

Retrieved on: 
星期二, 五月 9, 2023
Elasticity, Radical, Human, Food, Diet, TNF, Neutrophil, Cartilage, Inflammation, Element, Doctor of Philosophy, Haematococcus, Sunlight, Journal, Joint, Collagen, Cauchy stress tensor, Science and technology in Asia, III, Skin, Dietary supplement, Tanning (leather)

BRANCHBURG, N.J., May 9, 2023 /PRNewswire/ -- A study recently published in the Journal of Food & Nutritional Sciences, found that Lycored's astaxanthin prevented against collagen damage from neutrophils, discovering its potential to protect collagen and enhance skin health.

Key Points: 
  • BRANCHBURG, N.J., May 9, 2023 /PRNewswire/ -- A study recently published in the Journal of Food & Nutritional Sciences, found that Lycored's astaxanthin prevented against collagen damage from neutrophils, discovering its potential to protect collagen and enhance skin health.
  • This study assessed the addition of astaxanthin to neutrophils, the key players in the skin's immune response and photoaging, and the combined effects on collagen presence.
  • The addition of 50 uM of astaxanthin prevented collagen I loss by 28.1±8%, and collagen III loss by 49.4±5.9%.
  • Lycored's astaxanthin uses algae-derived (Haematococcus pluvialis) astaxanthin carotenoid with anti-oxidative and anti-inflammatory properties that provides a multitude of science-backed benefits.